SCHEMBL4025022

SCHEMBL4025022

CCCCCCCCCCCCNS(=O)(=O)c1ccc(CNCc2ccc(Oc3ccccc3)cc2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.49
HTT P42858 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.40
CA12 O43570 4/20 0.40
CA9 Q16790 4/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
MMP2 P08253 3/20 0.40
ALDH1A1 P00352 4/20 0.40
TP53 P04637 3/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
RECQL P46063 1/20 0.40
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.38
NPY1R P25929 1/20 0.38
NPY5R Q15761 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1856043 0.90 SMN1; SMN2 (0.56) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4019040 0.89 HTT (0.52) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4025020 0.86 TSHR (0.49) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4711874 0.83 SMN1; SMN2 (0.53) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL1854689 0.83 SMN1; SMN2 (0.44) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL1852234 0.81 HTT (0.51) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4715831 0.78 TSHR (0.60) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4717989 0.76 MEN1 (0.47) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4714650 0.76 MEN1 (0.47) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4019037 0.75 HTT (0.51) TSHRHTTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 TSHR 1632/4885HTT 4318/4885SMN1; SMN2 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.